Last reviewed · How we verify

Polyuria — Treatment Landscape & Competitive Intelligence

Polyuria (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Polyuria, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Ddavp DESMOPRESSIN Ferring Pharms Inc Factor VIII Activator Vasopressin V1b receptor 1978-01-01
Minirin Minirin Hormozgan University of Medical Sciences Oxytocin receptor, Vasopressin V1a receptor, Vasopressin V1b receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Ferring Pharms Inc · 1 drug in Polyuria
  2. Hormozgan University of Medical Sciences · 1 drug in Polyuria

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Polyuria:

Cite this brief

Drug Landscape (2026). Polyuria — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/polyuria. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing